PANCREATIC AND EXTRA PANCREATIC EFFECTS OF GLYMEPIRIDE

Authors

  • Kravchun N. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2015.3.16

Keywords:

hyperinsulinemia, glucose transporter, insulin resistance, insulin receptor substrate, diabetes mellitus, tumor necrosis factor-α, sulfonylurea receptor, internal potassium purifier channels

Abstract

Insulin resistance (IR) and hyperinsulinemia (GI) play a leading role in the development of macrovascular complications in type 2 diabetes mellitus (DM), which are the main cause of mortality in these patients. Taking into account the decisive importance of gluco- and lipotoxicity in the development of microangiopathies, the main goal of antidiabetic pharmacological correction is to influence IR and dysfunction of β-cells of the pancreas

References

Poltorak VV, Kravchun NO, Gorshuns’ka MJu. P robl Endokryn Patologii’ 2011; 2:79-87.

Pan’kiv, V. I. Mezhdunar Jendokrinol Zhurn 2011; 38(6):52-57.

Rosenstock J, Samols E, Muchmore DB, et al. Diabetes Care 1996; 19(11):1194-1199.

Aleksandrov AA. Consilium Medicum 2002; 4(10):551-554.

Dedov II, Balabolkin MI, Mamaeva GG. Insulinovaja rezistentnost’ i rol’ gormonov zhirovoj tkani v razvitii saharnogo diabeta: posobie dlja vrachej, Moskva , 2005: 88 p.

Kabadi UM. Managed Care 2004; 6:48-59.

Kaminskij AV. Mizhnar Endokrynol Zhurn 2011; 34(2):56-60.

Kaminskij AV. Mizhnar Endokrynol Zhurn 2011; 7(39):60-62.

Müller G, Hartz D, Punter J, et al. Biochem Biophys Acta 1994; 1191:267-277.

Del Guerra S, Parentini C, Bracci C, et al. Acta Diabetol 2000; 37:139-141.

UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.

Balabolkin MI, Klebanova EM, Kreminskaja VM. Mezhdunar Jendokrinol Zhurn 2010; 2(26):45-52.

Charpentier G, Fleury F, Kabir M, et al. Diabet Med 2001; 18(10):828-834.

Muller G. Mol Med 2000; 6:907-933.

Kihtjak OP, Neshheret OP. Eksperym ta Klinich Fiziologija i Biohimija 2011; 1:16-23.

Overkamp D, Vol. A, Maerker E, et al. Diabetes Care 2002; 25(11):2065-2073.

Mori R, Hirabara S, Hirata A, et al. Diabetes Obes Metab 2008; 10(7):596-600.

Poltorak VV, Gorshunskaja MJu. Liky Ukrai’ny 2010; 6(142):82-85.

Miki T, Nagashima K, Tashiro F, et al. Proc Natl Acad Sci 1998; 98:10402-10406.

Haupt A, Kausch C, Dahl D, et al. Diabetes Care 2002; 25:2119-2132.

Muller G, Geisen K, Satoh Y. Biochem Biophys Acta 1994; 1191:267-277.

Pessin JE, Thurmond DC, Elmendorf JC, et al. J Biol Chem 1999; 274:2593-2596.

Ashcroft FM, Gribble FM. J Diabetes Complic 2000; 14:192-196.

Kravchun NA. Primenenie amarila v kompleksnoj terapii saharnogo diabeta tipa 2 s metabolicheskim sindromom, Har’kov , 2004: 20 p.

Tsunekawa T, Hayashi T, Suzuki Y, et al. Diabetes Care 2003; 26:285-289.

Koshiba K, Nomuro M, Nakaya Y, et al. J Med Invest 2006; 53:87-94.

Yamauchi T, Kamon J, Monokoshi Y, et al. Nat Med 2002; 8:1288-1295.

Ouchi N, Kihara S, Arita Y, et al. Biochem J 1999; 100:2473-2476.

Ozes ON, Akca H, Mayo LD, et al. Proc Natl Acad Sci 2001; 98:4660-4645.

Jain R, Police S, Phelps K, et al. Biochem J 1999; 338:737-743.

Fukuen S, Iwaki M, Yasui A, et al. J Biol Chem 2005; 280:23653-23659.

Inukai K, Watanabe M, Nakashima Y, et al. Biochem Byophys Res Commun 2005; 328:484-490.

Mori Y, Komiya H, Kurokawa N, et al. Diabetes Obes Metab 2004; 6:28-34.

Skrobonskaja NA, Sokolova LK, Ostapenko TS. Simejna Medycyna 2008; 1:37-39.

Poltorak VV, Kravchun NA, Gorshunskaja MJu. Mizhnarod Endokrynol Zhurn 2011; 5(37):76-88.

Caulfield M, O’Brien K. Clin Diabetes 2002; 20(2):81-84.

Kabadi MU, Kabadi UM. Ann Pharmacother 2003; 37(11):1572-1576.

Briscoe VJ, Griffith ML, Davis SN. Expert Opin Drug Metab Toxicol 2010; 6:225-235.

Rudyk JuS. Zdorov’ja Ukrai’ny 2007; 12(1):71-73.

Fritsche A, Schweitzer MA, Haring HU. Ann Intern Med 2003; 138(12):952-959.

Dedov II. Saharnyj diabet: Rukovodstvo dlja vrachej, Moskva , 2003: 455 p.

Downloads

Published

2021-08-17

How to Cite

Kravchun, N. A. . (2021). PANCREATIC AND EXTRA PANCREATIC EFFECTS OF GLYMEPIRIDE. Problems of Endocrine Pathology, 53(3), 126-132. https://doi.org/10.21856/j-PEP.2015.3.16

Issue

Section

TO PRACTICING ENDOCRINOLOGISTS